Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine

European Journal of Pharmacology

Volumn 349, Issue 2-3, 1998, Pages 151-157

  Živin, Marko ^a   Šprah, Lilijana ^a   Sket, Dušan ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

6 Hydroxydopamine; Bromocriptine; Dopamine receptor; LEK 8829; Parkinsonism; Turning behavior

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BROMOCRIPTINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ERGOLINE DERIVATIVE; LEK 8829; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN INJURY; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPARKINSON AGENTS; BROMOCRIPTINE; DOPAMINE ANTAGONISTS; HALOPERIDOL; LYSERGIC ACID; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; STEREOTYPED BEHAVIOR;

EID: 0032557669     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00287-8     Document Type: Article

References (22)

1. Al-Semaan Y.M., Clay H.A., Meltzer H.Y. Clozapine in treatment of bromocriptine-induced psychosis. J. Clin. Psychopharmacol. 17:1997;127-128.
2. Calne D.B., Teychenne P.F., Claveria L.E., Eastman R., Greenacre J.K., Petrie A. Bromocriptine in parkinsonism. Br. Med. J. 4:1974;442-444.
3. 1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology. 94:1988;178-182.
4. Heal D.J., Green A.R., Buylaert W.A. Inhibition of apomorphine-, bromocriptine- and lergotrile-induced circling behaviour in rats by subsequent haloperidol administration. Neuropharmacology. 19:1980;133-137.
5. 1 receptor stimulation. J. Neurosci. 10:1990;2318-2329.
6. Jackson D.M., Jenkins O.F., Ross S.B. The motor effects of bromocriptine - a review. Psychopharmacology. 95:1988;433-446.
7. Johnson A.M., Loew D.M., Vigouret J.M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. Br. J. Pharmacol. 56:1976;59-68.
8. 2-receptor interaction in turning behaviour induced by dopamine agonists in 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 88:1988;69-74.
9. Krisch I., Bole-Vunduk B., Lavrič B., Ocvirk A., Pepelnak M., Budihna M.V., Sket D. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841. J. Pharmacol. Exp. Ther. 271:1994;343-352.
10. Krisch I., Ručman R., Lavrič A., Ocvirk M., Bole-Vunduk B. A new ergoline derivative, LEK-8829, as potential new antipsychotic drug. CNS Drug Rev. 2:1996;294-307.
11. Lees A.J., Haddad S., Shaw K.M., Kohout L.J., Stern G.M. Bromocriptine in parkinsonism. Arch. Neurol. 35:1978;503-505.
12. Montastruc J.L., Rascol O., Senard J.M. Current status of dopamine agonists in Parkinson's disease management. Drugs. 46:1993;384-393.
13. Paxinos, G., Watson, C., 1982. The Rat Brain in Stereotaxic Coordinates. Academic Press, Sidney.
14. 2 dopamine agonists on turning behaviour in rats. Brain Res. 384:1986;387-390.
15. 2 dopamine agonists have synergistic effects in the 6-hydroxydopamine circling model on the rat. Neuropharmacology. 27:1988;1257-1264.
16. Scholz E., Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur. Arch. Psychiatry Neurol. Sci. 235:1985;60-64.
17. 2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. J. Pharmacol. Exp. Ther. 247:1988;180-185.
18. 2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
19. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;69-93.
20. Ungerstedt U., Arbuthnott G.W. Qualitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
21. Waddington, J.L., Daly, S.A., 1993. Regulation of unconditioned motor behaviour by D1:D2 interactions. In: Waddington, J.L. (Ed.), D1:D2 Dopamine Receptor Interactions. Academic Press, London, pp. 51-78.
22. 1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions. Br. J. Pharmacol. 119:1996;1187-1196.